Summary
The decade-long legal battle over CRISPR-Cas9 patent rights has reached a critical inflection point. With the recent registration of ToolGen’s Ribonucleoprotein (RNP) delivery patents in both the US and Europe, the landscape of gene-editing IP is shifting from a binary struggle between the Broad Institute and UC Berkeley to a more complex, multi-party confrontation. This development places ToolGen in a formidable position to challenge established licensing structures and seek royalties from blockbuster therapies like Vertex and CRISPR Therapeutics’ Casgevy®.
The Event
In a series of landmark developments, the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have approved key patent applications from ToolGen, a biotechnology firm originally founded in South Korea. The patents specifically cover the introduction of CRISPR-Cas9 RNP complexes into mammalian cells—a method widely considered the most efficient and safest for clinical applications. Furthermore, recent rulings from the European Unified Patent Court (UPC) have established precedents for multinational injunctions, significantly raising the stakes for current therapy providers operating in the EU.
Context: The Interference and the RNP Factor
The CRISPR patent war has historically been centered on who first invented the application of the technology in eukaryotic (human/animal) cells. Under the pre-AIA (America Invents Act) \"first-to-invent\" system, the USPTO initiated interference proceedings (Interference Nos. 106,126 and 106,127) involving the Broad Institute, UC Berkeley (CVC), and ToolGen.
- Broad Institute: Holds the first-granted US patents for eukaryotic use.
- CVC (UC Berkeley/Doudna): Claims priority based on the earliest biochemical discovery.
- ToolGen: Asserts specific priority for the RNP-based delivery method in mammalian cells.
The strategic importance of RNP delivery cannot be overstated. Unlike DNA or RNA-based delivery, the RNP method introduces the pre-assembled Cas9 protein and guide RNA directly into the cell. This reduces the duration of Cas9 expression, minimizing \"off-target\" effects where the gene-editing tool cuts unintended parts of the genome. As the industry moves toward clinical commercialization, RNP has become the de facto standard, making ToolGen’s specific patents a potential \"bottleneck\" or \"must-license\" asset.
Implications for IP Practitioners and Industry
For patent attorneys and IP strategists, this case provides several vital lessons in multi-jurisdictional strategy and technological specificity.
1. The Return of the \"Senior Party\" Status
In the USPTO interference proceedings, ToolGen was designated as the \"Senior Party\" based on its priority date. This shifts the burden of proof to the Broad and CVC groups to prove they invented the technology earlier. For global legal ops teams, this highlights the necessity of maintaining meticulous laboratory notebooks and establishing early, defensible priority dates across multiple international offices.
2. The UPC as a Strategic Hammer
The European Unified Patent Court (UPC) has recently shown its willingness to issue cross-border injunctions. If ToolGen successfully asserts its newly registered European patents at the UPC, it could theoretically block the sale of CRISPR-based therapies across multiple EU member states simultaneously. This gives ToolGen immense leverage in settlement negotiations that the previous fragmented national court system did not allow.
3. Royalty Cascades and Licensing Risks
With therapies like Casgevy® priced at approximately $2.2 million per dose, the potential royalty obligations are staggering. Companies currently licensing exclusively from the Broad Institute or CVC may find themselves exposed to \"double-dipping\" or infringement claims from ToolGen. IP counsel must now perform exhaustive FTO (Freedom to Operate) analyses that account for ToolGen’s specific RNP claims.
Outlook: What to Watch
As we move through 2025 and 2026, the industry should monitor three key areas:
- The Final PTAB Decisions: The outcome of the US interference proceedings will determine the ultimate priority for eukaryotic CRISPR use in the world's largest healthcare market.
- UPC Case Law: Any infringement actions filed by ToolGen in the UPC will set the tone for how biotech patents are enforced in the new European era.
- Consolidated Licensing Pools: Given the overlapping claims, there may be a push toward a patent pool (similar to MPEG-LA for video standards) to prevent clinical progress from being paralyzed by litigation.
\"The CRISPR IP landscape is no longer a two-horse race. The inclusion of ToolGen’s RNP patents means that every commercial player must re-evaluate their licensing roadmap or face significant litigation risk in both the US and Europe.\"
